More data should mean less risk. In nonclinical development, that's not always true. In this episode, we explore the concept of data hormesis — the inflection point where accumulating more data stops reducing uncertainty and starts creating it. If your team is running another study because the last one didn't give you the answer you needed, this episode is for you.

Key takeaways:

• Data hormesis is the point where more information stops helping and starts obscuring the path forward — just like a drug that's beneficial at low doses and toxic at high ones
• Early in development, data reduce uncertainty. Beyond a certain point, signals compete for attention rather than converging toward resolution
• When decisions aren't defined early, data accumulation quietly becomes a substitute for judgment rather than a tool to support it
• The patterns are recognizable: equivocal findings trigger rework instead of interpretation, borderline results lead to more studies without clarity on what would actually change
• Programs that move efficiently to IND aren't the ones with the most data — they're the ones that decided early which risks are acceptable and which questions are worth answering now
• Data don't create strategy. They make strategy visible.

Links:

• Data Is Not Strategy on Amazon: https://a.co/d/02xUsV6K
• Work with Dessi: www.toxistrategy.com

The Nonclinical is hosted by Dessi McEntee, MS, DABT — board-certified toxicologist and Fractional Head of Toxicology. Subscribe to the newsletter on LinkedIn, take the course at nonclinical.academy, or work with Dessi at toxistrategy.com.

"No major findings." Three words that instantly lower the blood pressure of every executive in the room — and sometimes, quietly derail a program. In this episode, we unpack why a clean toxicology study can still leave your IND dangerously exposed, what teams consistently get wrong when they see no major findings, and why the absence of a finding is never the end of interpretation — it's where interpretation has to begin.

Key takeaways:

• "No major findings" describes what was not observed — it is not an interpretation of what the study resolved
• A clean study still leaves critical questions open: how close was exposure to the clinical range? What assumptions are now baked in about escalation?
• Once "no major findings" enters the conversation, behavior changes — dose rationales harden, exposure assumptions stop being tested, follow-on studies are designed from reassurance instead of uncertainty
• The consequence doesn't show up in nonclinical — it shows up at IND when you're asked to justify decisions you thought were already made
• Strong programs use clean studies as an opportunity to do more thinking, not less — documenting assumptions, defining boundaries, and stating explicitly what would change the program's direction

Links:

• Data Is Not Strategy on Amazon: https://a.co/d/02xUsV6K
• Work with Dessi: https://www.toxistrategy.com/

The Nonclinical is hosted by Dessi McEntee, MS, DABT — board-certified toxicologist and Fractional Head of Toxicology. Subscribe to the newsletter on LinkedIn, take the course at nonclinical.academy, or work with Dessi at toxistrategy.com.

"Our CRO has QA — we're covered." It's one of the most common phrases in biotech, and one of the most dangerous assumptions in nonclinical development. In this episode, we break down the critical difference between CRO QA and sponsor-side oversight, why GLP compliance and regulatory strategy are two completely different things, and what happens when nobody is doing the sponsor's job.

Key takeaways:

• CRO QA ensures the CRO complies with GLP — that's it. It does not ensure your study design supports your regulatory strategy
• When a protocol deviation occurs, CRO QA documents it perfectly — but nobody assesses whether it invalidates your NOAEL or affects your IND
• Big Pharma has five layers of oversight. Most biotechs have two and hope that's enough — the missing layer is sponsor-side QA
• Real-time study monitoring with a regulatory lens is what catches problems when you can still fix them, not six months later in the final report
• Most biotechs choose to do nothing by default — not because they've evaluated the risk, but because they don't know the gap exists

Links:

• Data Is Not Strategy on Amazon: https://a.co/d/02xUsV6K
• Work with Dessi: www.toxistrategy.com

The Nonclinical is hosted by Dessi McEntee, MS, DABT — board-certified toxicologist and Fractional Head of Toxicology. Subscribe to the newsletter on LinkedIn, take the course at nonclinical.academy, or work with Dessi at toxistrategy.com.

Most nonclinical teams spend a lot of time thinking about which studies to run. Almost none spend enough time thinking about when. In this episode, we unpack why study sequencing is one of the most consequential — and most consistently underestimated — decisions in IND-enabling development, and walk through the three sequencing mistakes that quietly accumulate risk while looking like efficiency.

Key takeaways:

• Sequencing is an informational problem, not a scheduling problem — and confusing the two is where programs get into trouble
• Running a GLP pivotal study before dose range is genuinely established is the most common and most costly sequencing mistake
• A clean NOAEL without any adverse effects at the high dose isn't a win — it's a failure to toxicologically characterize your margins
• Parallel execution without informational overlap isn't a compressed timeline — it's two separate bets running simultaneously with limited ability to course-correct
• Regulators aren't just evaluating what your data shows — they're evaluating whether your program was designed to answer the right questions in the right order

Links:

• Data Is Not Strategy on Amazon: https://a.co/d/0cDYM8vP

The Nonclinical is hosted by Dessi McEntee, MS, DABT — board-certified toxicologist and Fractional Head of Toxicology. Subscribe to the newsletter on LinkedIn, take the course at nonclinical.academy, or work with Dessi at toxistrategy.com.

The science is finished. The data is locked. So why is your IND still weeks away? In this episode, we pull back the curtain on one of the most consistent — and avoidable — sources of delay in nonclinical programs: the gap between data lock and final report delivery. We break down the legacy dual-track CRO workflow that's been quietly adding 8-10 weeks to timelines, and explore the single-track solution that's finally fixing it.

Key takeaways:

• Data lock is not the finish line — sponsors who treat it that way get blindsided every time
• The legacy dual-track system has two separate teams manually handling the same data, sequentially — and it was built for an era that no longer exists
• Manual transcription doesn't just slow things down, it introduces reconciliation risk that can cascade into regulatory rejection
• PointCross's single-track process runs report generation and SEND dataset preparation in parallel from a single source of truth — eliminating duplication entirely
• For CROs, slow turnaround is no longer just an operational issue — it's a competitive liability

The Nonclinical is hosted by Dessi McEntee, MS, DABT — board-certified toxicologist and Fractional Head of Toxicology. Subscribe to the newsletter on LinkedIn, take the course at nonclinical.academy, or work with Dessi at toxistrategy.com.

Before your drug ever reaches a human, it has to earn its way there — and toxicology is what makes or breaks that journey. In this episode, we break down why the toxicology program is the most critical piece of an IND package, what a well-executed tox program actually looks like, and why seeing toxicity in animals is not a red flag — it's exactly what you want. If you've ever sat in a meeting and wondered where tox fits into the bigger picture, this one's for you.

Key takeaways:

• Drug development has two phases: before and after IND clearance — and tox owns the first one
• A tox program with zero findings can actually be a bad sign — it may mean your compound isn't doing anything at all
• Every tox program is custom-built to the drug — size, type, mechanism, route, and indication all shape it
• NOAEL and MTD aren't just acronyms — they're the data points that directly determine your Phase 1 starting dose
• Once in the clinic, tox shifts from gatekeeper to tactical support role

Links:

• Online Course: www.nonclinical.academy
• Work with Dessi: www.toxistrategy.com

The Nonclinical is hosted by Dessi McEntee, MS, DABT — board-certified toxicologist and Fractional Head of Toxicology. Subscribe to the newsletter on LinkedIn, take the course at nonclinical.academy, or work with Dessi at toxistrategy.com.